ROCKVILLE, Md.--(BUSINESS WIRE)--Aug. 16, 2013--
Emergent BioSolutions Inc. (NYSE:EBS) announced today that Barry
Labinger has been named Executive Vice President and President,
Biosciences Division, reporting directly to Daniel J. Abdun-Nabi,
Emergent’s President and Chief Executive Officer. Mr. Labinger will be
responsible for the strategic direction and management of the company’s
biosciences division, including the development, manufacturing, and
commercialization of biosciences product candidates; the advancement of
partnering initiatives around Emergent’s biosciences programs and
platform technologies MVAtor™ (modified vaccinia Ankara) and ADAPTIR™
(Modular Protein Technology); and the integration of future product
acquisitions into the division.
“Barry brings to Emergent over two decades of extensive
biopharmaceutical experience that encompasses general management,
commercialization, and business development – core competencies that are
integral to achieving the goals we have set in our growth plan,” said
Daniel J. Abdun-Nabi, Emergent’s President and Chief Executive Officer.
“As we look to expand our portfolio with specialized products that
address the needs of hospitals and healthcare providers, Barry’s
expertise will help greatly in establishing Emergent in the commercial
marketplace.”
Mr. Labinger served as executive vice president and chief commercial
officer at Human Genome Sciences, Inc. from 2005 to 2012. He has held a
number of executive positions, including global head of 3M
Pharmaceuticals from 2002 to 2005, and senior vice president and general
manager commercial operations, and vice president, Enbrel marketing, at
Immunex Corp. from 2000 to 2002. Mr. Labinger has held a number of
leadership positions in pharmaceutical marketing at Bristol-Myers Squibb
from 1997 to 2000 and Abbott Laboratories from 1990 to 1997. Mr.
Labinger received his M.B.A. in Marketing, Finance and Management Policy
and B.A. in Economics from Northwestern University.
About Emergent BioSolutions
Emergent BioSolutions is a specialty pharmaceutical company seeking to
protect and enhance life by offering specialized products to healthcare
providers and governments to address medical needs and emerging health
threats. Additional information may be found at www.emergentbiosolutions.com.
Follow us on twitter: @emergentbiosolu.
Source: Emergent BioSolutions Inc.
Emergent BioSolutions Inc.
Investors Contact:
Robert G.
Burrows
Vice President, Investor Relations
301-795-1877
BurrowsR@ebsi.com
or
Media
Contact:
Tracey Schmitt
Vice President, Corporate
Communications
301-795-1800
SchmittT@ebsi.com
